Brown Advisory’s Amylyx Pharmaceuticals AMLX Stock Holding History

Brown Advisory’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$277K	Hold	19,930	–	–	﹤0.01%	1236
2025 Q4	$241K	Hold	19,930	–	–	﹤0.01%	1285
2025 Q3	$271K	Hold	19,930	–	–	﹤0.01%	1237
2025 Q2	$128K	Hold	19,930	–	–	﹤0.01%	1323
2025 Q1	$70.6K	Hold	19,930	–	–	﹤0.01%	1305
2024 Q4	$75.3K	Sell	19,930 -20	-0.1%	-$94	﹤0.01%	1321
2024 Q3	$64.6K	Sell	19,950 -11	-0.1%	-$25	﹤0.01%	1246
2024 Q2	$37.9K	Hold	19,961	–	–	﹤0.01%	1218
2024 Q1	$56.7K	Buy	19,961 +6,500	+48%	+$85K	﹤0.01%	1224
2023 Q4	$198K	Hold	13,461	–	–	﹤0.01%	1164
2023 Q3	$246K	Hold	13,461	–	–	﹤0.01%	1059
2023 Q2	$290K	Sell	13,461 -5,000	-27%	-$135K	﹤0.01%	1019
2023 Q1	$542K	Sell	18,461 -14,980	-45%	-$520K	﹤0.01%	894
2022 Q4	$1.24M	Sell	33,441 -10,000	-23%	-$355K	﹤0.01%	700
2022 Q3	$1.22M	Buy	+43,441	New	+$1.08M	﹤0.01%	667

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Brown Advisory's AMLX Position: Q1 2026 in Review

Brown Advisory held its Amylyx Pharmaceuticals (AMLX) position steady in Q1 2026 at 19,930 shares worth $277K. The position accounts for ﹤0.01% of the portfolio, ranked #1236.

Brown Advisory first reported a position in AMLX in Q3 2022 and has held it in 15 quarters since. The position peaked at $1.24M in Q4 2022. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

Brown Advisory held 19,930 shares of Amylyx Pharmaceuticals worth $277K as of Q1 2026.
Brown Advisory left its Amylyx Pharmaceuticals share count unchanged in Q1 2026.
Amylyx Pharmaceuticals made up ﹤0.01% of Brown Advisory's portfolio in Q1 2026, its #1236 holding.
Brown Advisory first reported a position in Amylyx Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
Brown Advisory's Amylyx Pharmaceuticals position peaked at $1.24M in Q4 2022.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Brown Advisory's 13F filing for Q1 2026, filed 15 May 2026.